Onbrez (indacaterol) / Novartis - LARVOL DELTA

INTRAVASCULAR LARGE B-CELL LYMPHOMA DIAGNOSED BY RENAL BIOPSY PRESENTING WITH NEPHROTIC SYNDROME (ISN-WCN 2026) - "His past history included hypertension, dyslipidemia, and chronic obstructive pulmonary disease, treated with amlodipine, atorvastatin, indacaterol, and silodosin...R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) was initiated, followed by high-dose methotrexate for CNS prophylaxis...This case emphasizes the importance of considering hematologic malignancy in the differential diagnosis of nephrotic syndrome with unexplained fever, even in the absence of hematologic abnormalities. Early renal biopsy allowed timely R-CHOP chemotherapy and resulted in favorable clinical and renal outcomes."

Biopsy • B Cell Lymphoma • Cardiovascular • Chronic Obstructive Pulmonary Disease • Diffuse Large B Cell Lymphoma • Dyslipidemia • Glomerulonephritis • Hematological Malignancies • Hypertension • Immunology • Large B Cell Lymphoma • Lymphoma • Metabolic Disorders • Nephrology • Non-Hodgkin’s Lymphoma • Pulmonary Disease • Renal Cell Carcinoma • Renal Disease • Respiratory Diseases • BCL6 • CD20 • IL2 • IRF4 • PTPRC

Targeted Pulmonary Delivery of Indacaterol/Ciclesonide: Advancing Asthma Therapy Through Liposomal Encapsulation (ATS 2026) - No abstract available

Asthma • Immunology • Respiratory Diseases

Optimizing spray-dried liposomes for pulmonary delivery: impact of lipids composition and of drying parameters using experimental design. (PubMed, Eur J Pharm Biopharm) - "Co-encapsulation of clinically relevant drug combinations (formoterol/budesonide and ciclesonide/indacaterol) produced uniform powders with efficient aerosolization, highlighting the therapeutic potential of these formulations. Collectively, these results establish a robust, scalable, and reproducible approach for designing liposomal DPIs, balancing formulation composition, excipient selection, and process parameters. This study demonstrates that strategic integration of scalable technologies can reconcile structural stability, aerodynamic performance, and manufacturability, paving the way for the industrial translation of liposomal dry powders for targeted pulmonary therapies, including asthma and chronic obstructive pulmonary disease (COPD)."

Journal • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Identification of Cepharanthine as a Potential Therapy of Acid Sphingomyelinase Deficiency by Reducing Cellular Sphingosylphosphorylcholine. (PubMed, J Inherit Metab Dis) - "Eight compounds, floxuridine, dexamethasone, indacaterol maleate, triethylenethiophosphoramide, cytarabine, doramectin, cepharanthine (CEP), and tetrandrine (TE), were identified to abate the accumulation of SPC in ASMD cells. Additionally, CEP could improve mitochondrial morphology and function, and stimulated lysosome biogenesis by promoting TFEB nuclear translocation in ASMD cells. These results suggest that CEP could potentially be developed as a promising candidate for treating ASMD."

Journal • Frontotemporal Lobar Degeneration • Genetic Disorders • Lysosomal Storage Diseases • Metabolic Disorders • Rare Diseases • TFEB

A UNIQUE CASE OF ASTHMA-COPD AND OBSTRUCTIVE SLEEP APNEA OVERLAP SYNDROME ASSOCIATED WITH RESTLESS LEG SYNDROME AND THROMBOCYTOPENIA (CHEST 2025) - "RLS was diagnosed using the International Restless Leg Syndrome Study Group (IRLSSG) criteria.The patient was started on CPAP, ICS budesonide , glycopyrronium bromide plus indacaterol and Pregabalin . CPAP being the mainstay treatment for OSA along with ICS and LABA for overlap syndrome automatically led to improvement in both RLS and thrombocytopenia. The mortality in COPD patients at ICU settings associated with thrombocytopenia is high, hence the importance of early diagnosis becomes crucial. Also, alleviating RLS greatly impacts the severity of dyspnea and overall well being as seen in this patient."

Clinical • Asthma • Chronic Obstructive Pulmonary Disease • Genetic Disorders • Hematological Disorders • Immunology • Infectious Disease • Inflammation • Movement Disorders • Obesity • Obstructive Sleep Apnea • Pulmonary Emphysema • Respiratory Diseases • Restless Legs Syndrome • Sleep Disorder • Thrombocytopenia

A Novel Metered Dose Inhaler Formulation of Triple-Drug Fixed-Dose Combination of Vilanterol, Glycopyrronium, and Fluticasone Furoate: A Phase III, Randomized, Multicenter Trial to Evaluate the Efficacy and Safety in Indian Patients With Uncontrolled Asthma. (PubMed, Clin Ther) - "Efficacy and safety of VIL-GLY-FF-MDI were found to be similar to those of IND-GLY-MF-DPI in Indian patients with persistent asthma. Clinical Trial Registry India identifier: CTRI/2024/01/061230."

Journal • P3 data • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

COPD Treatment with Beta 2-Adrenoreceptor Agonists: Medicinal Perspectives and Recent Advances. (PubMed, Mini Rev Med Chem) - "The current study emphasizes the rational development of lead candidates, including trantinterol, isopropyl, tert-butyl, and heterocyclic ring 2-amino-2-phenylethanol derivatives, 8-(2-amino-1-hydroxyethyl)-6-hydroxy-1,4- benzoxazine-3(4H)-one derivatives (non-substituted, methyl-substituted, dimethyl-substituted), 5- (2-amino-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one analogues, indacaterol analogues, saligenin antedrugs, and saligenin alkoxyalkylphenyl sulfonamide derivatives, accompanied by molecular docking studies.This paper also highlights numerous structure-activity relationship investigations and various novel β2 agonists currently in clinical trials and patents. The present review will significantly aid in fostering the research of COPD."

Journal • Chronic Obstructive Pulmonary Disease • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases • ADRB2

Real-world novel adverse drug reactions (ADRs) associated with indacaterol (ERS 2025) - "This study provides new insights into the safety profile of indacaterol, identifying potential ADRs not previously reported in clinical trials. Further research is necessary to confirm these findings."

Adverse drug reaction • Clinical • Real-world • Real-world evidence • Alzheimer's Disease • Asthma • Cardiovascular • Chronic Obstructive Pulmonary Disease • CNS Disorders • Cognitive Disorders • Congestive Heart Failure • Dementia • Glaucoma • Heart Failure • Immunology • Ophthalmology • Pulmonary Disease • Respiratory Diseases • Ventricular Tachycardia

Effectiveness Salmeterol-Fluticasone and Indacaterol on FEV1/FVC Post-Tuberculosis Patient at dr. H. Abdul Moeloek Hospital Lampung Province Indonesia (ERS 2025) - "Salmeterol-fluticasone improves lung function better compared to Indacaterol. Conclusions Salmeterol-fluticasone is effective in improving post-tuberculosis who experience a decreased in FEV1/FVC."

Clinical • Infectious Disease • Respiratory Diseases • Tuberculosis

A Comparison of the Molecular Pharmacological Properties of Current Short, Long, and Ultra-Long-Acting β2-Agonists Used for Asthma and COPD. (PubMed, Pharmacol Res Perspect) - "Few studies directly compare the molecular pharmacological properties of short (salbutamol, terbutaline, fenoterol), long (formoterol, salmeterol), and ultra-long-acting (indacaterol, olodaterol, vilanterol) β2-agonists. Comparison with other β-ligands suggests that affinity and duration could both be improved further. However, given the very wide range of molecular pharmacological properties of β-agonists that are clinically effective and widely used, non-pharmacological properties (physiochemical, patient factors, devices and combination inhaler availability) may be as important in final clinical patient outcomes as the molecular pharmacological properties of the individual β2-agonists themselves."

Clinical • Journal • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Identification of key modules and hub genes for sepsis-induced myopathy using weighted gene co-expression network analysis. (PubMed, Front Genet) - "Additionally, leveraging the Connectivity Map (CMAP) database allowed us to predict six potential pharmacological agents-halcinonide, lomitapide, TG-101348, GSK-690693, loteprednol, and indacaterol-that might serve as therapeutic interventions for SIM. This research advances our understanding of the molecular basis of SIM, presenting new diagnostic biomarkers and potential drug targets. Further studies with larger clinical datasets are warranted to validate these findings and explore the therapeutic potential of the identified drugs."

Journal • Infectious Disease • Inflammation • Myositis • Septic Shock • CXCL10 • IL6 • STAT1

Pathophysiology, clinical manifestation, and treatment of tuberculosis-associated chronic obstructive pulmonary disease: a narrative review. (PubMed, Ewha Med J) - "Treatment generally follows current COPD guidelines, advocating the use of long-acting bronchodilators and the selective application of inhaled corticosteroids. Studies have demonstrated that indacaterol significantly improves lung function and respiratory symptoms, while long-acting muscarinic antagonists have shown survival benefits."

Journal • Review • Bronchiectasis • Chronic Obstructive Pulmonary Disease • Fibrosis • Immunology • Infectious Disease • Inflammation • Pulmonary Disease • Respiratory Diseases • Tuberculosis

In-silico drug repositioning studies of Candida albicans Nitrogen permease reactivator 1 (Npr1) kinase. (PubMed, Sci Rep) - "The binding stability of Npr1 and Indacaterol complex was also verified through Principal Component Analysis. The result secured from these computational approaches and techniques established that the drug has the potential to be developed as an anti-candida lead targeting candidiasis."

Journal • Candidiasis

A cost-effectiveness analysis comparing single-inhaler extrafine beclomethasone/formoterol/glycopyrronium bromide against other SITTs in adult patients with uncontrolled asthma in England. (PubMed, Health Econ Rev) - "BDP/FOR/GLY MS and HS were a dominant treatment alternative compared with FF/UMEC/VI, both MS and HS, and IND/GLY/MF HS in patients with asthma uncontrolled by ICS/LABA."

HEOR • Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Formulation of a dry powder for inhalation combining ciclesonide and indacaterol maleate using spray drying. (PubMed, Int J Pharm) - "These results highlight the importance of advancing in vitro methods to better predict in vivo performance and support the development of more effective inhaled therapies. Overall, this work presents a stable, carrier-free inhalation powder with a novel drug combination that achieves efficient lung deposition and six-month stability."

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Genomic crosstalk between carbachol, a muscarinic receptor agonist, and the long-acting β2-adrenoceptor agonist, indacaterol, in human airway epithelial cells. (PubMed, J Pharmacol Exp Ther) - "Functional annotation of carbachol + indacaterol-regulated genes identified gene ontology terms associated with several themes, including inflammation. Interaction between a long-acting β2-adrenoceptor agonist and endogenous acetylcholine could, paradoxically, augment airway inflammation in patients with chronic obstructive pulmonary disease."

Journal • Chronic Obstructive Pulmonary Disease • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

From COPD to cancer: indacaterol's unexpected role in combating NSCLC. (PubMed, Front Pharmacol) - "Moreover, the combination of indacaterol with immune checkpoint inhibitors may further enhanced the inhibitory effects of indacaterol on NSCLC cells. Our study provides scientific evidence supporting the clinical application of indacaterol as a novel therapeutic strategy for NSCLC treatment."

IO biomarker • Journal • Chronic Obstructive Pulmonary Disease • Immunology • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pulmonary Disease • Respiratory Diseases • Solid Tumor • SLC16A3 • SLC2A1

Masterful ecofriendly maintainable spectrophotometric techniques for considering indacaterol acetate and mometasone furoate: full evaluation and comparison of their greenness, whiteness, and blueness profiles. (PubMed, Anal Methods) - "Ecological aspects of the developed work were evaluated and gave satisfactory results using several evaluation tools [such as NEMI, Eco-Scale (=93), GAPI, AGREE (=76)] for the greenness aspect, RGB (=96.3) for the whiteness aspect, and BAGI (=90) for the blueness aspect. Additionally, an environmental assessment and statistical comparisons were made using Student's t-test and the F-test with the published HPLC method and those methods currently in use."

Journal • Asthma • Immunology • Infectious Disease • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases

Efficacy of Indacaterol vs Tiotropium in COPD patients due to biomass exposure in improving quality of life and reducing symptoms. (PubMed, Respir Med) - P4 | "Neither TIO nor IND improved quality of life, nor dyspnea evaluated by the mMRC scale, but TIO did improve inspiratory capacity, and TIO and IND improved dyspnea evaluated by BDI/TDI."

HEOR • Journal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Drug-associated glaucoma: A real-world study based on the Food and Drug Administration adverse event reporting system database. (PubMed, Clin Exp Ophthalmol) - "Preventing drug-associated glaucoma is more effective than treatment. Identifying the risk and drug-induced times of systemic and ophthalmic drugs can reduce occurrence risk. Clinical practitioners should be vigilant and inform patients of these risks."

Adverse events • Journal • Real-world • Real-world evidence • Glaucoma • Ophthalmology

Pharmacokinetics of pulmonary indacaterol in rat lung using molecular imprinting solid-phase extraction coupled with RP-UPLC. (PubMed, Sci Rep) - "This study successfully developed and optimized MISPE cartridges using indacaterol as a template, enabling precise pharmacokinetic evaluation in rat lung tissues. The cartridges demonstrated high binding capacity and selectivity, providing crucial insights into the local exposure of indacaterol at its site of action."

Journal • PK/PD data • Preclinical • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Calmodulin triggers activity-dependent rRNA biogenesis via interaction with DDX21. (PubMed, J Neurosci) - "Using high-throughput screening, we identified the small molecules Batefenterol and Indacaterol that attenuate the CaM-DDX21 interaction and suppress nascent rRNA synthesis and axon growth in hippocampal neurons...Mechanistically, CaM interacts with DDX21, an RNA helicase directly associated with Pol I subunit, to regulate the transcription of rDNA. Our study demonstrates CaM as a messenger linking neuronal activity to ribosome-dependent protein biosynthesis."

Journal • DDX21

Clinically Relevant β2-agonists Induce and Augment Rhinovirus-induction of Asthma-relevant Pro-inflammatory Mediators in Human Bronchial Epithelial Cells (ATS 2024) - " BEAS-2B BECs were stimulated with SABAs (fenoterol, salbutamol), LABAs (formoterol, salmeterol), ultra-LABAs (indacaterol, olodaterol, vilanterol), short-acting (ipratropium) or long-acting (tiotropium, aclidinium, umeclidinium) muscarinic antagonists, at concentrations 0. β2-agonists upregulate BEC production of asthma-relevant pro-inflammatory mediators, while muscarinic antagonists do not. β2-agonists also augment RV-induction of disease-relevant mediators. Corticosteroid co-administration abolishes these pro-inflammatory effects."

Clinical • Late-breaking abstract • Asthma • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases • BDNF • IL6

The optimal dose of indacaterol for treatment of chronic obstructive pulmonary disease: a systematic review and Bayesian network meta-analysis. (PubMed, J Thorac Dis) - "However, the quality of available evidence limits the formation of powerful conclusions regarding the comparative efficacy or safety of different doses of indacaterol used to treat COPD. Higher-quality randomized controlled trials (RCTs) are required for further research in the future."

Journal • Retrospective data • Review • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Evaluating β2-agonists as siRNA delivery adjuvants for pulmonary surfactant-coated nanogel inhalation therapy. (PubMed, Eur J Pharm Biopharm) - "As opposed to the least hydrophobic drugs salbutamol and formoterol, the more hydrophobic long-acting β2-agonist (LABA) salmeterol promoted siRNA delivery in both cell types for both uncoated and surfactant-coated nanogels, whereas indacaterol showed this effect solely in lung epithelial cells. Our results demonstrate the potential of both salmeterol and indacaterol to be repurposed as adjuvants for nanocarrier-mediated siRNA delivery to the lung, which could provide opportunities for drug combination therapy."

Journal • Pulmonary Disease • Respiratory Diseases